Aminolevulinic acid
Aminolevulinic acid (Ala), also known as 5-aminolevulinic acid (5-Ala), is a naturally occurring, non-proteinogenic amino acid that serves as the universal precursor to the tetrapyrrole biosynthetic pathway in virtually all living organisms.
Aminolevulinic acid (Ala), also known as 5-aminolevulinic acid (5-Ala), is a naturally occurring, non-proteinogenic amino acid that serves as the universal precursor to the tetrapyrrole biosynthetic pathway in virtually all living organisms. It is synthesized endogenously from Glycine and succinyl-CoA in a reaction catalyzed by Ala synthase, and subsequently undergoes a series of enzymatic transformations that culminate in the formation of heme, chlorophyll, and other biologically essential porphyrins. Within mammalian cells, 5-Ala is preferentially taken up and metabolized in tissues with high metabolic activity — most notably neoplastic cells — where it accumulates as the fluorescent photosensitizer protoporphyrin IX (PpIX). This selective intracellular accumulation underpins 5-Ala's dual utility as both a diagnostic fluorophore and a photodynamic/radiodynamic agent, making it a molecule of considerable pharmacological interest.
As a therapeutic and theranostic agent, 5-Ala exploits the preferential accumulation of PpIX in tumor tissue. Upon activation by light of appropriate wavelength, PpIX generates reactive oxygen species (ROS) that induce localized cytotoxic effects — a process central to photodynamic Therapy (PDT). Beyond PDT, 5-Ala's PpIX-mediated fluorescence enables real-time intraoperative tumor visualization. These properties have positioned 5-Ala at the intersection of oncology, photomedicine, and precision surgery, with an expanding evidence base across dermatologic, gynecologic, neurologic, and musculoskeletal malignancies including ovarian cancer and breast cancer.
Rebuilt from PubMed 19 Sept 2026 · no new papers today
Where the papers sit
10 papers study aminolevulinic acid directly. The themes below are drawn from those 10. 1 paradigm shift and 1 new direction follow.
-
Targeted Photodynamic Cancer Therapy : ALA-based photodynamic therapy is moving toward theranostic and combination strategies that improve tumor selectivity while limiting skin photosensitivity. PpIX generation, cathepsin B activation, nanoprobes, and photothermal or chemotherapeutic combinations recur across cancer applications. 5 papers · 50%
-
Fluorescence-Guided Glioblastoma Surgery : 5-ALA and sodium fluorescein are being evaluated as complementary tools for defining glioblastoma margins and increasing extent of resection. The recurring endpoints are FLAIR-volume resection, progression-free survival, and overall survival, without a consistent shift toward one agent. 2 papers · 20%
-
Others — ALA Therapy and Biosynthesis : Radiodynamic therapy with 5-ALA is being explored for osteosarcoma, including local delivery and xenograft treatment, while separate work engineers E. coli for higher ALA production. These applications share ALA but do not form a unified biological or clinical direction. 3 papers · 30%
In IDH-wildtype glioblastoma, 5-ALA does not consistently provide a resection advantage over sodium fluorescein
The single-center IDH-wildtype glioblastoma cohort and the multicenter fluorescence-guided glioblastoma cohort both found that 5-ALA did not outperform sodium fluorescein on the principal resection measures: the former found no significant difference in contrast-enhancing, FLAIR, or total extent of resection, while the latter found contrast-enhancement-defined gross-total resection more often with sodium fluorescein than with 5-ALA 42749959Sep 42649357Aug. This replaces the assumption that selecting 5-ALA necessarily improves tumor removal, although the single-center study still associated 5-ALA use with longer progression-free survival.
Engineered Escherichia coli can serve as a high-yield manufacturing platform for 5-ALA
The metabolically engineered Escherichia coli production strain treated 5-ALA not as a tumor-localizing precursor, photosensitizer, imaging agent, or component of a therapeutic construct, but as the product of an industrial biosynthetic process, reaching 55.11 g/L in a 5-L bioreactor 42231739Jun. This gives 5-ALA a distinct role as a manufactured agricultural and pharmaceutical commodity and shifts the focus from using the molecule in biological treatment to producing it at scale.
Recent Findings on aminolevulinic acid
Photodynamic Cancer Theranostics: ALA-based photodynamic therapy uses tumor-selective protoporphyrin IX (PpIX) generation for treatment and fluorescence detection, while newer derivatives address bioavailability and tissue penetration 42061135Apr. 89-ALA showed stronger spheroid penetration, photodynamic therapy, and tumor-confined fluorescence than ALA and hexyl-ALA in ovarian cancer models 42061135Apr. Dual-masked, cathepsin B-activated prodrugs improved stability, membrane permeability, PpIX accumulation, and phototoxicity, with compound 4b outperforming parent 5-ALA in MDA-MB-231 cells 42430823Jul. DPH combined cisplatin, ALA, and deferasirox to generate PpIX in tumors while avoiding skin photosensitivity, whereas CuS-ALA nanoprobes added photoacoustic and fluorescence imaging, drug-efflux modulation, and near-infrared photothermal therapy 42504784Jul42013020Apr. ALA-PDT produced high short-term responses in localized extramammary Paget's disease, but responses declined by 12 months and favored lesions measuring 5 cm or less without exudation 42545809Aug.
Fluorescence-Guided Glioblastoma Surgery: 5-ALA and Sodium fluorescein produced different resection and survival patterns in IDH-wildtype glioblastoma, depending on the imaging endpoint. A single-center study found no significant fluorophore differences in contrast-enhancement-defined or FLAIR extent of resection, but 5-ALA was associated with longer progression-free and overall survival 42749959Sep. A multicenter cohort found higher contrast-enhancement-defined gross total resection and greater contrast-enhancing extent of resection with Sodium fluorescein than with 5-ALA. However, institutional practices and case selection attenuated these differences, and no center-independent survival advantage remained 42649357Aug. These findings support prospective testing of whether 5-ALA identifies biologically selective resection within FLAIR-hyperintense regions.
Radiodynamic Therapy with 5-ALA enhanced radiation therapy against osteosarcoma in cell and animal investigations, while local administration suppressed tumor volume after a reduced dose in xenografts 42203311May42665407Aug. The locally administered regimen produced greater tumor growth suppression than control or irradiation alone without significant body-weight changes or abnormal behavior 42665407Aug. Systematic metabolic engineering of Escherichia coli established a separate production pathway by combining glycine-degradation control, nonoxidative glycolysis, enhanced glucose uptake, efflux engineering, antioxidant systems, and heme-flux attenuation. The engineered A48 strain produced 55.11 g/L of 5-ALA within 41 hours in a 5 L bioreactor 42231739Jun.
Written from 10 PubMed abstracts, each one cited by PMID above. Published: 2026-06-15. Last written: 2026-09-18 by GPT. Drafted by language models from published abstracts; not medical advice.